Diaverum withdraws initial public offering
Following the announcement of its intention to float on 16 November 2020, Diaverum AB (publ.) (“Diaverum” or the “Company”), a leading global dialysis provider, today announces it will not proceed with the planned listing on Nasdaq Stockholm.Martin Dunn, member of the board of directors of Diaverum and partner at Bridgepoint, commented: “Despite strong interest from potential investors, including several high quality pension funds, who recognised Diaverum’s impressive underlying performance and ability to grow both revenues and earnings year on year, indications received did not fully